Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00078013 · ClinicalTrials.gov registry record · Phase 2

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

A Phase 2 study of Myocardial Infarction, sponsored by Tanabe Pharma Corporation.

Completed
Registry status
Phase 2
Development phase
414
Enrollment target
1
Study location

NCT00078013 is a Phase 2 study of Myocardial Infarction that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 414 participants, below the 4,675-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00078013, a Phase 2 study of Myocardial Infarction, has completed, sponsored by Tanabe Pharma Corporation.

COMPLETED
Registry status
Phase 2
Development phase
414 participants
Enrollment target
1
Study location

Study Summary

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary objectives of this study are to examine the safety, tolerability, and efficacy of intravenous MCC-135 in limiting final infarct size, as measured by single photon emission computed tomography (SPECT), in patients who require percutaneous coronary intervention (PCI) for a first-documented ST-segment elevation acute myocardial infarction (AMI).

Conditions Studied

Interventions

  • DRUG MCC-135

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital/ Harvard Medical School - Boston

Trial Details

FieldValue
Enrollment Target 414 participants
Start Date 2003-04
Est. Completion 2004-08
Phase Phase 2

Sponsor

Tanabe Pharma Corporation

7 total trials

What the Registry Record Tells You About NCT00078013

The ClinicalTrials.gov registry entry for NCT00078013 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,675-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (91% lower). The listed sponsor is Tanabe Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which MCC-135 is the first listed.

NCT00078013 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00078013 about?

NCT00078013 is a clinical study titled "MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients". This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary objectives of this study are to examine the safety, tolerability, and efficacy of intravenous MCC-135 in limiting final infarct size, as measured by single photon emission computed tomography (SPECT...

What is the current status of trial NCT00078013?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 414 participants. The study started on 2003-04. Estimated completion is 2004-08.

What conditions does trial NCT00078013 study?

This clinical trial studies the following conditions: Myocardial Infarction.

What interventions are being tested in trial NCT00078013?

The interventions under investigation include: MCC-135 (DRUG).

Who is sponsoring clinical trial NCT00078013?

This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00078013 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.